September 12, 2019 08:59 AM EDT
R&D
Pharma

Roche's Tecen­triq ex­cels in an­oth­er lung can­cer study

Natalie Grover

Reporter

Months af­ter se­cur­ing FDA ap­proval for Tecen­triq as a first line of de­fense — in com­bi­na­tion with chemother­a­py — in ex­ten­sive-stage small-cell lung can­cer pa­tients, Roche …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

A service from the Financial Times